We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cold-chain support and smart expiry detection can cut waste, boost safety and improve inventory visibility.
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, recently advanced its pharmacy automation portfolio in the United States with the deployment of BD Vmax 160, its next-generation pharmacy automation robot at Fairview Health Services. The technology is designed to help high-volume centralized outpatient pharmacies manage the growing complexity of specialty and refrigerated medications while increasing fulfillment capacity and improving medication access.
Per management, the future of pharmacy care will ever more depend on efficient and scalable models that can meet patients’ needs while expanding access to therapies. BD believes Fairview’s investment in centralized pharmacy operations and intelligent automation demonstrates how health systems can modernize pharmacy services, improve efficiency and serve their communities better.
Likely Trend of BDX Stock Following the News
Following the announcement, BDX stock gained 2.8% at yesterday’s close. Year to date, shares of the company have lost 5.8% against the industry’s 5% growth. The S&P 500 has risen 11.1% in the same timeframe.
The U.S. deployment of BD Vmax 160 could strengthen BD’s position in the expanding pharmacy automation market. As demand rises for specialty therapies, biologics, GLP-1 medications and refrigerated medicines, health systems are likely to seek automation capable of handling more complex fulfillment requirements. BD’s expanding portfolio of robotics and connected pharmacy solutions could support long-term demand, improve operational efficiency for customers and create opportunities for further adoption of its pharmacy automation technologies.
BDX currently has a market capitalization of $49 billion.
Image Source: Zacks Investment Research
More on the Deployment
BD Vmax 160 is designed specifically for centralized fulfillment environments, automating labor-intensive pharmacy workflows. Its BD EasyLoad system enables overnight inventory replenishment, with a reported three-second loading time per tote and 99.8% accuracy. Automated labeling also helps reduce manual work while supporting labeling requirements across all 50 states.
Another major capability is cold-chain support for medications requiring storage between 2°C and 8°C. The system also features smart expiry detection, which tracks expiration dates when medications are loaded and automatically prevents expired products from being dispensed. These capabilities can help pharmacies improve inventory visibility, reduce waste and strengthen medication safety.
Fairview, which fills an average of 20,000 prescriptions per week across 25 outpatient pharmacies and mail-order services in Minnesota, is the first U.S. health system to deploy the system. Fairview’s deployment builds on its existing collaboration with BD, including the BD Parata Max 2 high-speed vial filling robot. Alongside the BD Incada Connected Care Platform and other automation technologies, Vmax 160 advances BD’s broader vision of a connected, intelligent end-to-end pharmacy ecosystem.
Factors Favoring the Market
According to data provided by Grand View Research, the global pharmacy automation devices market is estimated to be $7.9 billion in 2026 and is expected to witness a CAGR of 7.5% through 2033.
Factors such as the rising adoption of automated dispensing systems, increasing need to improve pharmacy efficiency, growing focus on medication safety and the expanding use of centralized pharmacy operations are expected to support market growth.
Other News
BD is advancing its advanced tissue regeneration strategy through two key clinical milestones. The company recently announced that the STANCE trial of GalaFLEX LITE Scaffold surpassed 50% of its maximum planned enrollment, with 274 patients treated across 33 U.S. sites.
BD also completed enrollment of 477 patients across 32 U.S. and European sites in the PREVENT trial evaluating Phasix Mesh for incisional hernia prevention. Both studies are designed to generate clinical evidence that could support future FDA submissions and expand the applications of BD’s regenerative technologies.
Veracyte, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
Globus Medical, currently sporting a Zacks Rank #2 (Buy), reported second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
View the Zacks #1 Rank List
Image: Bigstock
BDX Deploys Vmax 160 to Advance Intelligent Pharmacy Automation
Key Takeaways
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, recently advanced its pharmacy automation portfolio in the United States with the deployment of BD Vmax 160, its next-generation pharmacy automation robot at Fairview Health Services. The technology is designed to help high-volume centralized outpatient pharmacies manage the growing complexity of specialty and refrigerated medications while increasing fulfillment capacity and improving medication access.
Per management, the future of pharmacy care will ever more depend on efficient and scalable models that can meet patients’ needs while expanding access to therapies. BD believes Fairview’s investment in centralized pharmacy operations and intelligent automation demonstrates how health systems can modernize pharmacy services, improve efficiency and serve their communities better.
Likely Trend of BDX Stock Following the News
Following the announcement, BDX stock gained 2.8% at yesterday’s close. Year to date, shares of the company have lost 5.8% against the industry’s 5% growth. The S&P 500 has risen 11.1% in the same timeframe.
The U.S. deployment of BD Vmax 160 could strengthen BD’s position in the expanding pharmacy automation market. As demand rises for specialty therapies, biologics, GLP-1 medications and refrigerated medicines, health systems are likely to seek automation capable of handling more complex fulfillment requirements. BD’s expanding portfolio of robotics and connected pharmacy solutions could support long-term demand, improve operational efficiency for customers and create opportunities for further adoption of its pharmacy automation technologies.
BDX currently has a market capitalization of $49 billion.
Image Source: Zacks Investment Research
More on the Deployment
BD Vmax 160 is designed specifically for centralized fulfillment environments, automating labor-intensive pharmacy workflows. Its BD EasyLoad system enables overnight inventory replenishment, with a reported three-second loading time per tote and 99.8% accuracy. Automated labeling also helps reduce manual work while supporting labeling requirements across all 50 states.
Another major capability is cold-chain support for medications requiring storage between 2°C and 8°C. The system also features smart expiry detection, which tracks expiration dates when medications are loaded and automatically prevents expired products from being dispensed. These capabilities can help pharmacies improve inventory visibility, reduce waste and strengthen medication safety.
Fairview, which fills an average of 20,000 prescriptions per week across 25 outpatient pharmacies and mail-order services in Minnesota, is the first U.S. health system to deploy the system. Fairview’s deployment builds on its existing collaboration with BD, including the BD Parata Max 2 high-speed vial filling robot. Alongside the BD Incada Connected Care Platform and other automation technologies, Vmax 160 advances BD’s broader vision of a connected, intelligent end-to-end pharmacy ecosystem.
Factors Favoring the Market
According to data provided by Grand View Research, the global pharmacy automation devices market is estimated to be $7.9 billion in 2026 and is expected to witness a CAGR of 7.5% through 2033.
Factors such as the rising adoption of automated dispensing systems, increasing need to improve pharmacy efficiency, growing focus on medication safety and the expanding use of centralized pharmacy operations are expected to support market growth.
Other News
BD is advancing its advanced tissue regeneration strategy through two key clinical milestones. The company recently announced that the STANCE trial of GalaFLEX LITE Scaffold surpassed 50% of its maximum planned enrollment, with 274 patients treated across 33 U.S. sites.
BD also completed enrollment of 477 patients across 32 U.S. and European sites in the PREVENT trial evaluating Phasix Mesh for incisional hernia prevention. Both studies are designed to generate clinical evidence that could support future FDA submissions and expand the applications of BD’s regenerative technologies.
Becton, Dickinson and Company Price
Becton, Dickinson and Company price | Becton, Dickinson and Company Quote
BDX’s Zacks Rank & Key Picks
Currently, BDX carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) , Globus Medical (GMED - Free Report) and West Pharmaceutical (WST - Free Report) .
Veracyte, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
Globus Medical, currently sporting a Zacks Rank #2 (Buy), reported second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.